BamSEC and AlphaSense Join Forces
Learn More

Tcr2 Therapeutics Inc

Formerly NASDAQ: TCRR
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.2
from 8-K 6 pages Lease Modification Agreement
12/34/56
EX-10.1
from 8-K 4 pages Assignment of Lease
12/34/56
EX-10.3
from 8-K 3 pages First Amendment to Employment Agreement
12/34/56
EX-10.3
from 425 3 pages First Amendment to Employment Agreement
12/34/56
EX-10.2
from 8-K 6 pages Voting and Support Agreement
12/34/56
EX-10.2
from 425 6 pages Voting and Support Agreement
12/34/56
EX-10.1
from 425 6 pages Voting and Support Agreement
12/34/56
EX-10.1
from 8-K 6 pages Voting and Support Agreement
12/34/56
EX-10.13
from 10-K 17 pages Tcr2 Therapeutics Inc. 2022 Inducement Plan
12/34/56
EX-10.1
from 10-Q 39 pages Lease Agreement
12/34/56
EX-10.1
from 10-Q 1 page Tcr2 Therapeutics Inc. Amendment No. 1 to 2018 Stock Option and Incentive Plan
12/34/56
EX-10.4
from S-1/A 12 pages Tcr2 Therapeutics Inc. 2018 Employee Stock Purchase Plan
12/34/56
EX-10.2
from S-1/A 47 pages Tcr2 Therapeutics Inc. 2018 Stock Option and Incentive Plan
12/34/56
EX-10.15
from S-1 63 pages Dated December 18, 2018 (1) Tcr2 Therapeutics Inc. - And - (2) Cell Therapy Catapult Limited Collaboration Agreement
12/34/56
EX-10.14
from S-1 2 pages Letter Agreement
12/34/56
EX-10.13
from S-1 5 pages Royalty Transfer Agreement
12/34/56
EX-10.12
from S-1 7 pages Tcr2 Therapeutics, Inc. Consulting Agreement
12/34/56
EX-10.11
from S-1 20 pages Tcr2 Therapeutics Inc. Amended and Restated Consulting Agreement
12/34/56
EX-10.10
from S-1 7 pages Tcr2, Inc. Consulting Agreement
12/34/56
EX-10.9
from S-1 24 pages [***] Indicates Material That Has Been Omitted and for Which Confidential Treatment Has Been Requested. All Such Omitted Material Has Been Filed With the Securities and Exchange Commission Pursuant to Rule 406 Promulgated Under the Securities Act of 1933, as Amended License Agreement
12/34/56